A multi-center, randomized, double-blind, placebo-controlled, parallel group study to preliminarily evaluate the safety, tolerability, pharmacokinetics and efficacy of CFZ533 in patients with moderate to severe myasthenia gravis

Trial Profile

A multi-center, randomized, double-blind, placebo-controlled, parallel group study to preliminarily evaluate the safety, tolerability, pharmacokinetics and efficacy of CFZ533 in patients with moderate to severe myasthenia gravis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Apr 2017

At a glance

  • Drugs CFZ 533 (Primary)
  • Indications Myasthenia gravis
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 10 Apr 2017 Planned primary completion date changed from 27 Dec 2017 to 31 Jul 2017.
    • 12 Sep 2016 Planned End Date changed from 1 Jan 2018 to 1 Dec 2017.
    • 12 Sep 2016 Planned primary completion date changed from 1 Jan 2018 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top